From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Canwell Biotech Ltd. has described antibody-drug conjugates (ADCs) comprising an antibody covalently linked to a Toll-like receptor 7 (TLR7) and TLR8 agonist through a cleavable or noncleavable linker ...

The sale of FibroGen China to AstraZeneca PLC simplifies the company's operations and cleans up its balance sheet, CEO Thane ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation ...